DRAK2 Antikörper (AA 351-365)

Produktnummer ABIN1886873

Der Kaninchen Polyklonal anti-DRAK2 Antikörper wird verwendet zum Nachweis von DRAK2 in Proben von Human. Er wurde validiert für ELISA, WB und ICC.

Kurzübersicht für DRAK2 Antikörper (AA 351-365) (ABIN1886873)

Target: DRAK2 (STK17B) (serine/threonine Kinase 17b (STK17B))

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser DRAK2 Antikörper ist unkonjugiert

Applikation: ELISA, Western Blotting (WB), Immunocytochemistry (ICC)

Produktdetails anti-DRAK2 Antikörper

Bindungsspezifität: AA 351-365

Kreuzreaktivität (Details): It has no cross responses to DAP or ZIP kinases. The approximately 70 kDa band is probably non-related to DRAK2 although it is peptide blockable.

Aufreinigung: Ion exchange chromatography purified

Immunogen: Peptide corresponding to amino acids 351 to 365 of human DRAK2.

Anwendungsinformationen

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: PBS containing 0.02 % sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: WARNING: Reagents contain sodium azide. Sodium azide is very toxic if ingested or inhaled. Avoid contact with skin, eyes, or clothing. Wear eye or face protection when handling. If skin or eye contact occurs, wash with copious amounts of water. If ingested or inhaled, contact a physician immediately. Sodium azide yields toxic hydrazoic acid under acidic conditions. Dilute azide-containing compounds in running water before discarding to avoid accumulation of potentially explosive deposits in lead or copper plumbing.

Handhabung: Avoid freezing and thawing repeatly.

Lagerung: 4 °C/-20 °C

Informationen zur Lagerung: Store at 4 °C for short term use.Store at -20 °C for long term preservation.

Details zu DRAK2

Target: DRAK2 (STK17B) (serine/threonine Kinase 17b (STK17B))

Andere Bezeichnung: DRAK2

Hintergrund: Apoptosis is mediated by death domain containing adapter molecules and a caspase family of proteases.Certain serine/threonine protein kinases, such as ASK-1 and RIP, are mediators of apoptosis.Two novel serine/threonine kinases that induce apoptosis were recently identified and designated DRAK1 and DRAK2 (for DAP kinase-related apoptosis-inducing protein kinases).DRAKs contain an N-terminal kinase domain and a C-terminal regulation domain.Overexpression of DRAK2 induces apoptosis.DRAKs have high sequence homology to DAP and ZIP kinases, and they represent a novel family of serine/threonine kinases, which mediates apoptosis through their catalytic activities.DRAK2 is located in nucleus and the messenger RNA was ubiquitously expressed in human tissues.